OrthoPediatrics (KIDS) to Release Earnings on Thursday

OrthoPediatrics (NASDAQ:KIDS) is anticipated to post its Q4 2025 results after the market closes on Thursday, February 26th. Analysts expect the company to announce earnings of ($0.29) per share and revenue of $61.2720 million for the quarter. Investors may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Thursday, February 26, 2026 at 4:30 PM ET.

OrthoPediatrics Trading Down 3.9%

KIDS stock opened at $16.30 on Tuesday. The company has a market capitalization of $408.80 million, a PE ratio of -8.36 and a beta of 1.12. The company’s 50 day moving average price is $17.64 and its two-hundred day moving average price is $18.18. The company has a debt-to-equity ratio of 0.28, a quick ratio of 3.52 and a current ratio of 7.40. OrthoPediatrics has a one year low of $15.28 and a one year high of $26.40.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Russell Investments Group Ltd. boosted its holdings in OrthoPediatrics by 433.1% in the third quarter. Russell Investments Group Ltd. now owns 1,402 shares of the company’s stock valued at $26,000 after purchasing an additional 1,139 shares during the last quarter. Northwestern Mutual Wealth Management Co. grew its stake in shares of OrthoPediatrics by 5,226.5% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 2,610 shares of the company’s stock worth $46,000 after purchasing an additional 2,561 shares in the last quarter. Caption Management LLC acquired a new stake in shares of OrthoPediatrics in the third quarter valued at $54,000. BNP Paribas Financial Markets boosted its stake in shares of OrthoPediatrics by 60.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 3,288 shares of the company’s stock worth $61,000 after acquiring an additional 1,235 shares in the last quarter. Finally, State of Wyoming raised its stake in OrthoPediatrics by 189.7% during the 4th quarter. State of Wyoming now owns 6,822 shares of the company’s stock valued at $121,000 after purchasing an additional 4,467 shares during the period. 69.05% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities research analysts have commented on the company. Canaccord Genuity Group assumed coverage on OrthoPediatrics in a report on Wednesday, December 10th. They issued a “buy” rating and a $24.00 target price on the stock. BTIG Research reiterated a “buy” rating and issued a $23.00 price target on shares of OrthoPediatrics in a research report on Wednesday, October 29th. Weiss Ratings restated a “sell (e+)” rating on shares of OrthoPediatrics in a research note on Thursday, January 22nd. TD Cowen upgraded shares of OrthoPediatrics to a “strong-buy” rating in a research note on Tuesday, January 27th. Finally, Needham & Company LLC lowered their price target on shares of OrthoPediatrics from $42.00 to $26.00 and set a “buy” rating on the stock in a report on Wednesday, October 29th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $23.89.

OrthoPediatrics Company Profile

OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.

The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.